Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29


Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness.

Boileau M, Shirinian M, Gayden T, Harutyunyan AS, Chen CCL, Mikael LG, Duncan HM, Neumann AL, Arreba-Tutusaus P, De Jay N, Zeinieh M, Rossokhata K, Zhang Y, Nikbakht H, Mouawad C, Massoud R, Frey F, Nasr R, El Cheikh J, El Sabban M, Kleinman CL, Mahfouz R, Minden MD, Jabado N, Bazarbachi A, Eppert K.

Nat Commun. 2019 Jun 28;10(1):2891. doi: 10.1038/s41467-019-10705-z.


Drosophila Tet Is Expressed in Midline Glia and Is Required for Proper Axonal Development.

Ismail JN, Badini S, Frey F, Abou-Kheir W, Shirinian M.

Front Cell Neurosci. 2019 Jun 4;13:252. doi: 10.3389/fncel.2019.00252. eCollection 2019.


Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening.

Outa AA, Abubaker D, Bazarbachi A, Sabban ME, Shirinian M, Nasr R.

Haematologica. 2020 Jan 31;105(2):387-397. doi: 10.3324/haematol.2019.219394. Print 2020.


Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster.

Berlandi J, Chaouch A, De Jay N, Tegeder I, Thiel K, Shirinian M, Kleinman CL, Jeibmann A, Lasko P, Jabado N, Hasselblatt M.

Neuro Oncol. 2019 May 6;21(5):628-639. doi: 10.1093/neuonc/noz021.


Epstein-Barr Virus DNA Enhances Diptericin Expression and Increases Hemocyte Numbers in Drosophila melanogaster via the Immune Deficiency Pathway.

Sherri N, Salloum N, Mouawad C, Haidar-Ahmad N, Shirinian M, Rahal EA.

Front Microbiol. 2018 Jun 11;9:1268. doi: 10.3389/fmicb.2018.01268. eCollection 2018.


The HTLV-1 oncoprotein Tax is modified by the ubiquitin related modifier 1 (Urm1).

Hleihel R, Khoshnood B, Dacklin I, Omran H, Mouawad C, Dassouki Z, El-Sabban M, Shirinian M, Grabbe C, Bazarbachi A.

Retrovirology. 2018 Apr 17;15(1):33. doi: 10.1186/s12977-018-0415-4.


Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age.

Fontebasso AM, Shirinian M, Khuong-Quang DA, Bechet D, Gayden T, Kool M, De Jay N, Jacob K, Gerges N, Hutter B, Şeker-Cin H, Witt H, Montpetit A, Brunet S, Lepage P, Bourret G, Klekner A, Bognár L, Hauser P, Garami M, Farmer JP, Montes JL, Atkinson J, Lambert S, Kwan T, Korshunov A, Tabori U, Collins VP, Albrecht S, Faury D, Pfister SM, Paulus W, Hasselblatt M, Jones DT, Jabado N.

Oncotarget. 2015 Oct 13;6(31):31844-56. doi: 10.18632/oncotarget.5571.


A Transgenic Drosophila melanogaster Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1-Driven Transformation In Vivo.

Shirinian M, Kambris Z, Hamadeh L, Grabbe C, Journo C, Mahieux R, Bazarbachi A.

J Virol. 2015 Aug;89(15):8092-5. doi: 10.1128/JVI.00918-15. Epub 2015 May 20.


Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation.

Shirinian M, Kfoury Y, Dassouki Z, El-Hajj H, Bazarbachi A.

Front Microbiol. 2013 Aug 15;4:231. doi: 10.3389/fmicb.2013.00231. eCollection 2013.


Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.

Jacob K, Quang-Khuong DA, Jones DT, Witt H, Lambert S, Albrecht S, Witt O, Vezina C, Shirinian M, Faury D, Garami M, Hauser P, Klekner A, Bognar L, Farmer JP, Montes JL, Atkinson J, Hawkins C, Korshunov A, Collins VP, Pfister SM, Tabori U, Jabado N.

Clin Cancer Res. 2011 Jul 15;17(14):4650-60. doi: 10.1158/1078-0432.CCR-11-0127. Epub 2011 May 24.


BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma.

Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U.

Clin Cancer Res. 2011 Jul 15;17(14):4790-8. doi: 10.1158/1078-0432.CCR-11-0034. Epub 2011 May 24.


Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma.

Al-Halabi H, Nantel A, Klekner A, Guiot MC, Albrecht S, Hauser P, Garami M, Bognar L, Kavan P, Gerges N, Shirinian M, Roberge D, Muanza T, Jabado N.

Acta Neuropathol. 2011 Feb;121(2):229-39. doi: 10.1007/s00401-010-0780-0. Epub 2010 Nov 24.


The Rap1 guanine nucleotide exchange factor C3G is required for preservation of larval muscle integrity in Drosophila melanogaster.

Shirinian M, Popovic M, Grabbe C, Varshney G, Hugosson F, Bos H, Rehmann H, Palmer RH.

PLoS One. 2010 Mar 3;5(3):e9403. doi: 10.1371/journal.pone.0009403. Erratum in: PLoS One. 2010;5(3). doi: 10.1371/annotation/c3ebafa0-1531-4e9f-ab3a-660db7b8dcd2.


Fusion of circular and longitudinal muscles in Drosophila is independent of the endoderm but further visceral muscle differentiation requires a close contact between mesoderm and endoderm.

Wolfstetter G, Shirinian M, Stute C, Grabbe C, Hummel T, Baumgartner S, Palmer RH, Holz A.

Mech Dev. 2009 Aug-Sep;126(8-9):721-36. doi: 10.1016/j.mod.2009.05.001. Epub 2009 May 20.


Drosophila Anaplastic Lymphoma Kinase regulates Dpp signalling in the developing embryonic gut.

Shirinian M, Varshney G, Lorén CE, Grabbe C, Palmer RH.

Differentiation. 2007 Jun;75(5):418-26. Epub 2007 Feb 5.


[Pharmacology and pharmacy on the INTERNET].

Medvedev OS, Kerbikov OB, Prokhorov AV, Shirinian ME.

Eksp Klin Farmakol. 1997 Sep-Oct;60(5):83-8. Russian.


A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck.

Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Dunnington JS, Hong WK.

Am J Clin Oncol. 1996 Aug;19(4):379-82.


Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.

Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Earley CL, Winn RJ, Brooks J, Baez L, Hong WK.

Ann Oncol. 1995 Jan;6(1):83-5.


Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.

Huber MH, Shirinian M, Lippman SM, Dimery IW, Frankenthaler RA, Hong WK.

Invest New Drugs. 1994;12(3):223-9.


Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck.

Huber MH, Dimery IW, Benner SE, Lippman SM, Shirinian M, Esparaz B, Frenning D, Guillory-Perez C, Hong WK.

Invest New Drugs. 1994;12(4):327-31.


Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience.

Shirinian MH, Weber RS, Lippman SM, Dimery IW, Earley CL, Garden AS, Michaelson J, Morrison WH, Kramer A, Byers R, et al.

Head Neck. 1994 Jan-Feb;16(1):39-44.


Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report.

Shirinian M, Lee JS, Dhingra HH, Greenberg J, Hong WK.

Semin Oncol. 1992 Dec;19(6 Suppl 12):58-63.


Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.

Shirinian M, Lee JS, Dhingra HH, Greenberg J, Hong WK.

Semin Oncol. 1992 Feb;19(1 Suppl 1):49-53.


Phase II trial of carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck.

Dimery IW, Brooks BJ, Winn R, Martin T, Shirinian M, Hong WK.

J Clin Oncol. 1991 Nov;9(11):1939-44.


Adjuvant surgery in the multimodality treatment of small-cell lung cancer.

Holoye PY, Shirinian M.

Am J Clin Oncol. 1991 Jun;14(3):251-3. No abstract available.


Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.

Lee JS, Murphy WK, Shirinian MH, Pang A, Hong WK.

Cancer Chemother Pharmacol. 1991;28(3):199-204.


PI-PB rollover in a group of aged listeners.

Shirinian MJ, Arnst DJ.

Ear Hear. 1980 Jan-Feb;1(1):50-3.


Supplemental Content

Loading ...
Support Center